Market Summary
USD255.65+0.41
Market Closed0.16%
UTHR Alerts
UTHR Stock Price
UTHR RSI Chart
UTHR Valuation
UTHR Price/Sales (Trailing)
UTHR Profitability
UTHR Fundamentals
UTHR Revenue
UTHR Earnings
Price Action
52 Week Range
283.09
(Low)(High)
Last 7 days
-2.9%
Last 30 days
-7.4%
Last 90 days
-3.3%
Trailing 12 Months
28.0%
UTHR Financial Health
UTHR Investor Care
Peers (Alternatives to United Therapeutics)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
BGNE | 336.2B | 1.2B | 1.59% | 13.84% | -159.75 | 269.02 | 17.64% | -57.08% |
ABBV | 257.0B | 57.8B | -12.85% | 4.71% | 19.17 | 4.45 | 4.80% | 77.95% |
REGN | 82.3B | 15.0B | 4.45% | 23.71% | 15.33 | 5.14 | 21.25% | -46.28% |
VRTX | 79.2B | 8.7B | 6.32% | 26.84% | 24.19 | 9.1 | 22.03% | 50.41% |
ALNY | 27.2B | 960.9M | -1.80% | 48.64% | -22.99 | 28.28 | 28.24% | -41.08% |
UTHR | 11.6B | 1.9B | -7.43% | 27.95% | 16.47 | 6.26 | 12.37% | 52.98% |
SRPT | 10.6B | 876.0M | -1.21% | 59.04% | -14.8 | 12.1 | 35.70% | -47.34% |
| MID-CAP | ||||||||
MDGL | 4.7B | 504.0K | -2.18% | 252.25% | -17.17 | 2.5K | -66.53% | -15.89% |
RARE | 3.3B | 343.4M | 2.10% | -31.74% | -4.92 | 9.72 | -4.50% | -90.69% |
MRTX | 3.1B | - | 19.78% | -55.50% | -4.19 | 917.1 | - | -52.72% |
BPMC | 2.7B | 272.3M | -2.18% | -43.09% | -3.82 | 10.07 | -18.36% | -74.56% |
| SMALL-CAP | ||||||||
CPRX | 1.7B | 191.8M | -17.30% | 147.86% | 25.21 | 8.8 | 43.59% | 60.82% |
MGNX | 350.9M | 93.0M | 0.18% | -51.94% | -1.84 | 3.77 | -19.83% | -30.37% |
CRBP | 20.6M | - | 13.38% | -60.95% | -0.49 | 19.11 | -77.61% | 5.14% |
CYTK | 4.2M | - | 4.24% | 28.70% | -0.01 | 63.29 | 26.15% | -23.38% |
Financials for United Therapeutics
| Income Statement (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 |
| Revenue | 4.0% | 1,860 | 1,789 | 1,768 | 1,686 | 1,655 |
| Gross Profit | 3.7% | 1,723 | 1,661 | 1,633 | 1,563 | 1,577 |
| S&GA Expenses | -4.3% | 480 | 501 | 444 | - | - |
| R&D Expenses | -4.0% | 312 | 325 | 305 | 540 | 583 |
| Costs and Expenses | -1.6% | 886 | 900 | 860 | 1,130 | 1,204 |
| EBITDA | 12.9% | 988 | 875 | 939 | 662 | - |
| EBITDA Margin | 8.6% | 0.53* | 0.49* | 0.53* | 0.39* | - |
| Earnings Before Taxes | 13.4% | 912 | 804 | 870 | 594 | 568 |
| EBT Margin | 9.1% | 0.49* | 0.45* | 0.49* | 0.35* | - |
| Interest Expenses | 22.8% | 25 | 20 | 19 | 19 | 19 |
| Net Income | 12.1% | 707 | 631 | 687 | 476 | 462 |
| Net Income Margin | 7.8% | 0.38* | 0.35* | 0.39* | 0.28* | - |
| Free Cahsflow | 4.2% | 679 | 652 | 673 | 477 | - |
* denotes actual numbers (not divided by Millions)
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 |
| Assets | 4.3% | 5,782 | 5,543 | 5,360 | 5,169 | 5,049 |
| Current Assets | 13.9% | 3,056 | 2,684 | 2,587 | 2,324 | 2,386 |
| Cash Equivalents | 21.6% | 967 | 795 | 813 | 895 | 909 |
| Inventory | 1.2% | 91 | 90 | 88 | 94 | 97 |
| Net PPE | 6.2% | 841 | 791 | 784 | 781 | 727 |
| Goodwill | - | 28 | - | - | - | - |
| Liabilities | -0.4% | 1,219 | 1,225 | 1,184 | 1,210 | 1,219 |
| Current Liabilities | -4.7% | 316 | 332 | 293 | 305 | 320 |
| Shareholder's Equity | 5.6% | 4,562 | 4,318 | 4,176 | 3,959 | 3,830 |
| Retained Earnings | 5.1% | 4,910 | 4,671 | 4,555 | 4,315 | 4,203 |
| Additional Paid-In Capital | 1.0% | 2,315 | 2,292 | 2,254 | 2,245 | 2,226 |
| Accumulated Depreciation | 3.4% | 377 | 364 | 352 | 342 | - |
| Shares Outstanding | 0.2% | 46 | 45 | 45 | 45 | 45 |
* denotes actual numbers (not divided by Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 |
| Cashflow From Operations | 9.4% | 849 | 776 | 797 | 598 | 550 |
| Share Based Compensation | -23.7% | 87 | 114 | 77 | 139 | 188 |
| Cashflow From Investing | 14.8% | -818.00 | -959.90 | -839.80 | -486.90 | -354.90 |
| Cashflow From Financing | -25.9% | 27 | 37 | 24 | 45 | 43 |
Risks for UTHR
What is the probability of a big loss on UTHR?
73.8%
Probability that United Therapeutics stock will be more than 20% underwater in next one year
31.1%
Probability that United Therapeutics stock will be more than 30% underwater in next one year.
12.7%
Probability that United Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does UTHR drawdown profile look like?
Y-axis is the maximum loss one would have experienced if United Therapeutics was unfortunately bought at previous high price.
Drawdowns
Returns for UTHR
Cumulative Returns on UTHR
16.9%
10-Year Cumulative Returns
11.5%
7-Year Cumulative Returns
15.2%
5-Year Cumulative Returns
36.5%
3-Year Cumulative Returns
What are the long-term rolling returns for UTHR?
FIve years rolling returns for United Therapeutics.
Annualized Returns
Which funds bought or sold UTHR recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-02-06 | WESTPAC BANKING CORP | new | - | 2,600,980 | 2,600,980 | 0.04% |
2023-02-06 | Glassman Wealth Services | reduced | -2.34 | 7,761 | 34,761 | 0.01% |
2023-02-06 | SYNOVUS FINANCIAL CORP | new | - | 250,281 | 250,281 | -% |
2023-02-06 | Daiwa Securities Group Inc. | added | 8.28 | 16,000 | 51,000 | -% |
2023-02-06 | LOS ANGELES CAPITAL MANAGEMENT LLC | added | 109.49 | 18,216,400 | 28,436,400 | 0.14% |
2023-02-06 | Retirement Systems of Alabama | reduced | -0.99 | 8,798,350 | 36,727,300 | 0.16% |
2023-02-06 | Symmetry Investments LP | new | - | 4,629,000 | 4,629,000 | 1.24% |
2023-02-06 | Bogart Wealth, LLC | new | - | 10,289 | 10,289 | -% |
2023-02-06 | Parallel Advisors, LLC | added | 5.03 | 37,483 | 133,483 | 0.01% |
2023-02-06 | Pacer Advisors, Inc. | reduced | -87.71 | -14,718,000 | 2,871,000 | 0.01% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
UTHR Alerts
United Therapeutics News
Schedule 13G FIlings of United Therapeutics
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 06, 2023 | wellington management group llp | 5.64% | 2,569,263 | SC 13G | |
| Feb 02, 2023 | rothblatt martine a | 8.0% | 3,919,603 | SC 13G/A | |
| Jan 24, 2023 | blackrock inc. | 9.9% | 4,510,211 | SC 13G/A | |
| Feb 11, 2022 | renaissance technologies llc | 6.48% | 2,917,191 | SC 13G/A | |
| Feb 11, 2022 | avoro capital advisors llc | 6.7% | 3,035,000 | SC 13G/A | |
| Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A | |
| Feb 04, 2022 | rothblatt martine a | 8.5% | 4,118,487 | SC 13G/A | |
| Feb 03, 2022 | blackrock inc. | 9.4% | 4,239,175 | SC 13G/A | |
| Mar 01, 2021 | rothblatt martine a | 7.6% | 3,629,486 | SC 13G/A | |
| Feb 12, 2021 | avoro capital advisors llc | 6.4% | 2,850,000 | SC 13G |
UTHR Fair Value
Recent SEC filings of United Therapeutics
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Feb 07, 2023 | 4 | Insider Trading | |
| Feb 06, 2023 | SC 13G | Major Ownership Report | |
| Feb 06, 2023 | SC 13G/A | Major Ownership Report | |
| Feb 03, 2023 | SC 13G/A | Major Ownership Report | |
| Feb 03, 2023 | SC 13G | Major Ownership Report | |
| Feb 03, 2023 | 4 | Insider Trading | |
| Feb 02, 2023 | 4 | Insider Trading | |
| Feb 02, 2023 | 4 | Insider Trading | |
| Feb 02, 2023 | SC 13G/A | Major Ownership Report | |
| Feb 02, 2023 | SC 13G/A | Major Ownership Report |
Latest Insider Trading transactions for UTHR
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-02-02 | MAHON PAUL A | sold | -1,527,790 | 254.632 | -6,000 | evp & general counsel |
2023-02-02 | ROTHBLATT MARTINE A | sold | -2,052,910 | 256.614 | -8,000 | chairperson & ceo |
2023-02-02 | MAHON PAUL A | acquired | 721,560 | 120.26 | 6,000 | evp & general counsel |
2023-02-02 | ROTHBLATT MARTINE A | acquired | 904,640 | 113.08 | 8,000 | chairperson & ceo |
2023-02-01 | SULLIVAN LOUIS W | acquired | 92,610 | 132.3 | 700 | - |
2023-02-01 | SULLIVAN LOUIS W | sold | -182,931 | 261.33 | -700 | - |
2023-02-01 | ROTHBLATT MARTINE A | acquired | 904,640 | 113.08 | 8,000 | chairperson & ceo |
2023-02-01 | ROTHBLATT MARTINE A | sold | -2,079,600 | 259.951 | -8,000 | chairperson & ceo |
2023-01-31 | ROTHBLATT MARTINE A | acquired | 904,640 | 113.08 | 8,000 | chairperson & ceo |
2023-01-31 | ROTHBLATT MARTINE A | sold | -2,092,020 | 261.503 | -8,000 | chairperson & ceo |
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
UTHR Income Statement
2022-09-30Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions | 3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
| Revenues: | ||||
| Total revenues | $ 516.0 | $ 444.7 | $ 1,444.8 | $ 1,270.3 |
| Operating expenses: | ||||
| Cost of product sales | $ 37.2 | $ 27.7 | $ 92.8 | $ 87.9 |
| Cost, product and service | Net product sales | Net product sales | Net product sales | Net product sales |
| Research and development | $ 66.1 | $ 79.2 | $ 229.0 | $ 457.2 |
| Selling, general, and administrative | 98.4 | 109.1 | 318.9 | 339.1 |
| Total operating expenses | 201.7 | 216.0 | 640.7 | 884.2 |
| Operating income | 314.3 | 228.7 | 804.1 | 386.1 |
| Interest income | 13.3 | 3.8 | 24.4 | 12.5 |
| Interest expense | (9.2) | (4.6) | (20.1) | (13.9) |
| Other (expense) income, net | (5.9) | (23.5) | (34.9) | 71.0 |
| Impairments of investments in privately-held companies | 0.0 | 0.0 | (1.7) | (2.3) |
| Total other (expense) income, net | (1.8) | (24.3) | (32.3) | 67.3 |
| Income before income taxes | 312.5 | 204.4 | 771.8 | 453.4 |
| Income tax expense | (73.2) | (41.7) | (176.6) | (89.8) |
| Net income | $ 239.3 | $ 162.7 | $ 595.2 | $ 363.6 |
| Net income per common share: | ||||
| Basic (in dollars per share) | $ 5.26 | $ 3.62 | $ 13.14 | $ 8.12 |
| Diluted (in dollars per share) | $ 4.91 | $ 3.42 | $ 12.35 | $ 7.72 |
| Weighted average number of common shares outstanding: | ||||
| Basic (in shares) | 45.5 | 44.9 | 45.3 | 44.8 |
| Diluted (in shares) | 48.7 | 47.6 | 48.2 | 47.1 |
| Net product sales | ||||
| Revenues: | ||||
| Total revenues | $ 516.0 | $ 444.7 | $ 1,434.8 | $ 1,270.3 |
| Other | ||||
| Revenues: | ||||
| Total revenues | $ 0.0 | $ 0.0 | $ 10.0 | $ 0.0 |
UTHR Balance Sheet
2022-09-30Consolidated Balance Sheets - USD ($) $ in Millions | Sep. 30, 2022 | Dec. 31, 2021 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 966.8 | $ 894.8 |
| Marketable investments | 1,648.8 | 1,035.9 |
| Accounts receivable, no allowance for 2022 and 2021 | 231.7 | 198.7 |
| Inventories, net | 91.0 | 93.8 |
| Other current assets | 118.1 | 100.4 |
| Total current assets | 3,056.4 | 2,323.6 |
| Marketable investments | 1,443.8 | 1,649.9 |
| Goodwill and other intangible assets, net | 44.5 | 44.6 |
| Property, plant, and equipment, net | 840.8 | 780.9 |
| Deferred tax assets, net | 281.3 | 261.9 |
| Other non-current assets | 114.8 | 108.2 |
| Total assets | 5,781.6 | 5,169.1 |
| Current liabilities: | ||
| Accounts payable and accrued expenses | 220.1 | 174.6 |
| Share tracking awards plan | 60.1 | 102.4 |
| Other current liabilities | 35.7 | 28.4 |
| Total current liabilities | 315.9 | 305.4 |
| Line of credit | 800.0 | 800.0 |
| Other non-current liabilities | 103.5 | 104.8 |
| Total liabilities | 1,219.4 | 1,210.2 |
| Commitments and contingencies | ||
| Stockholders’ equity: | ||
| Preferred stock, par value $.01, 10,000,000 shares authorized, no shares issued | 0.0 | 0.0 |
| Common stock, par value $.01, 245,000,000 shares authorized, 72,182,311 and 71,727,021 shares issued, and 45,563,095 and 45,107,805 shares outstanding at September 30, 2022 and December 31, 2021, respectively | 0.7 | 0.7 |
| Additional paid-in capital | 2,314.6 | 2,245.4 |
| Accumulated other comprehensive loss | (84.1) | (23.0) |
| Treasury stock, 26,619,216 shares at September 30, 2022 and December 31, 2021 | (2,579.2) | (2,579.2) |
| Retained earnings | 4,910.2 | 4,315.0 |
| Total stockholders’ equity | 4,562.2 | 3,958.9 |
| Total liabilities and stockholders’ equity | $ 5,781.6 | $ 5,169.1 |